STEM Times of Connecticut
SEE OTHER BRANDS

Your best source on science and technology news from Connecticut

STEM Times of Connecticut: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on STEM Times of Connecticut.

Press releases published on May 7, 2025

XRP News Today: From AI to Real-World Assets: How Vaultro Finance Unlocks Tokenized Exposure on the XRP Ledger

XRP News Today: From AI to Real-World Assets: How Vaultro Finance Unlocks Tokenized Exposure on the XRP Ledger

SINGAPORE, May 07, 2025 (GLOBE NEWSWIRE) -- In the rapid growing world of decentralized finance, Vaultro Finance is carving out a unique and powerful niche. As the first decentralized index fund protocol built on the XRP Ledger, Vaultro enables a new …

Oculis to Present at Upcoming May Investor Conferences

Oculis to Present at Upcoming May Investor Conferences

ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, …

UNICOM Engineering Announces Strategic Partnership with E4 Computer Engineering to Deliver Advanced AI Infrastructure Solutions

UNICOM Engineering Announces Strategic Partnership with E4 Computer Engineering to Deliver Advanced AI Infrastructure Solutions

CANTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- UNICOM Engineering announces a strategic partnership with E4 Computer Engineering, the Italian leader in High-Performance Computing (HPC) and AI-driven solutions. This collaboration expands UNICOM Engineering …

Intchains Group Limited to Report Unaudited First Quarter 2025 Financial Results on Thursday, May 22, 2025

Intchains Group Limited to Report Unaudited First Quarter 2025 Financial Results on Thursday, May 22, 2025

SINGAPORE, May 07, 2025 (GLOBE NEWSWIRE) -- Intchains Group Limited (Nasdaq: ICG) (“we,” or the “Company”), a company that engages in the provision of altcoin mining products, the strategic acquisition and holding of Ethereum-based cryptocurrencies, and …

CLINUVEL recruits 200 patients in  Phase III vitiligo trial CUV105

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Executive summary Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved Randomised trial, 20-week treatment protocol plus 6-month follow up Study sites in North America, Africa and Europe First clinical …

BioAegis Therapeutics Announces Site Activation and Patient Recruitment Underway in 13 Countries in Phase 2b Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

BioAegis Therapeutics Announces Site Activation and Patient Recruitment Underway in 13 Countries in Phase 2b Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens. Results from this landmark study expected to inform therapeutic strategies beyond ARDS, …

ZenaTech expande su oficina en Irlanda ofreciendo Dron como Servicio (DaaS), incluyendo agricultura de precisión, a un mercado europeo con un crecimiento anual del 28,6%

ZenaTech expande su oficina en Irlanda ofreciendo Dron como Servicio (DaaS), incluyendo agricultura de precisión, a un mercado europeo con un crecimiento anual del 28,6%

VANCOUVER, Columbia Británica, May 06, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), una empresa de tecnología especializada en drones con IA (inteligencia artificial), Dron como un Servicio (DaaS), soluciones …

Optigo Biotherapeutics Wins People’s Choice Award at Eyecelerator and Presents Compelling Preclinical Data on Long-Acting Intravitreal Biologics at the ARVO 2025 Conference

Optigo Biotherapeutics Wins People’s Choice Award at Eyecelerator and Presents Compelling Preclinical Data on Long-Acting Intravitreal Biologics at the ARVO 2025 Conference

Optigo wins People’s Choice Award at the recent Eyecelerator meeting in Park City for proprietary drug anchoring, potential to transform intravitreal drug delivery Preclinical data demonstrates sustained efficacy and safety for six months or more following …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service